BeOne Medicines director granted 18,980 ONC shares

HOOPER ANTHONY C reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

HOOPER ANTHONY C reported acquisition or exercise transactions in this Form 4 filing.

BeOne Medicines Ltd. director Anthony C. Hooper received an equity grant of 18,980 Ordinary Shares in the form of restricted share units at no cash cost on 2026-06-11. These restricted share units vest on the earlier of the first anniversary of the grant date or the next annual general meeting, subject to continued board service and any accelerated vesting provisions under the company’s Independent Non-Executive Director Compensation Policy. Following this grant, Hooper holds 83,720 Ordinary Shares directly.

Insider Trade Summary

Grant/Award: 18,980 shares

Grant/Award 1 txn

Insider HOOPER ANTHONY C

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares	18,980	$0.00	$0.00

Holdings After Transaction: Ordinary Shares — 83,720 shares (Direct)

Footnotes (1)

1. F1. Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless there is a triggering event of accelerated vesting pursuant to the Company's Independent Non-Executive Director Compensation Policy.

Key Figures

RSU grant size: 18,980 shares Grant price: $0.0000 per share Total holdings after grant: 83,720 shares +1 more

4 metrics

RSU grant size 18,980 shares Restricted share unit award on 2026-06-11

Grant price $0.0000 per share Stated transaction price for RSU grant

Total holdings after grant 83,720 shares Ordinary Shares directly held following transaction

Vesting condition Earlier of 1-year anniversary or next AGM RSU vesting schedule subject to continued board service

Key Terms

restricted share units, annual general meeting, Independent Non-Executive Director Compensation Policy

3 terms

restricted share units financial

"Represents securities underlying restricted share units. The restricted share units shall become fully vested..."

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

annual general meeting regulatory

"fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting"

Independent Non-Executive Director Compensation Policy financial

"unless there is a triggering event of accelerated vesting pursuant to the Company's Independent Non-Executive Director Compensation Policy"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BeOne Medicines (ONC) report for Anthony C. Hooper?

BeOne Medicines reported that director Anthony C. Hooper received 18,980 Ordinary Shares as a restricted share unit grant. The award was made at no cash cost and is part of his equity compensation for board service, increasing his direct holdings to 83,720 shares.

How many BeOne Medicines (ONC) shares did Anthony C. Hooper receive and at what price?

Anthony C. Hooper received 18,980 Ordinary Shares through a restricted share unit grant, with a stated price of $0.0000 per share. This indicates a compensation award rather than an open-market purchase, aligning with typical director equity compensation structures.

When do Anthony C. Hooper’s restricted share units in BeOne Medicines (ONC) vest?

The restricted share units granted to Anthony C. Hooper vest on the earlier of the first anniversary of the grant date or the date of the next annual general meeting. Vesting continues only while he serves as a director, subject to any accelerated vesting triggers.

What happens to Anthony C. Hooper’s BeOne Medicines restricted units if he leaves the board?

If Anthony C. Hooper resigns from the board or otherwise stops serving as a director, all vesting of these restricted share units ceases. An exception applies only if there is a triggering event for accelerated vesting under the company’s Independent Non-Executive Director Compensation Policy.

How many BeOne Medicines (ONC) shares does Anthony C. Hooper own after this Form 4?

After the reported grant, Anthony C. Hooper directly holds 83,720 Ordinary Shares of BeOne Medicines. This total includes the 18,980 shares represented by the newly granted restricted share units reported in the Form 4 insider transaction filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 05:50 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HOOPER ANTHONY C

(Last) (First) (Middle)

C/O BEONE MEDICINES I GMBH

AESCHENGRABEN 27, 21ST FLOOR

(Street)

BASEL 4051

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
BeOne Medicines Ltd. [ ONC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	06/11/2026		A		18,980	A	$0	83,720	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless there is a triggering event of accelerated vesting pursuant to the Company's Independent Non-Executive Director Compensation Policy.

Remarks:

	/s/ Qing Nian, as Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)